Lansing Street Advisors’s AstraZeneca AZN Stock Holding History

Lansing Street Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$34.3K	Hold	240	–	–	0.02%	157
2023 Q1	$33.3K	Buy	240 +3	+1%	+$404	0.02%	170
2022 Q4	$32.1K	Buy	237 +1	+0.4%	+$125	0.02%	185
2022 Q3	$26K	Buy	236 +1	+0.4%	+$127	0.02%	163
2022 Q2	$31K	Hold	235	–	–	0.02%	148
2022 Q1	$33K	Buy	+235	New	+$28.2K	0.02%	160

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Lansing Street Advisors's AZN Position: Q2 2023 in Review

Lansing Street Advisors held its AstraZeneca (AZN) position steady in Q2 2023 at 240 shares worth $34.3K. The position accounts for 0.02% of the portfolio, ranked #157.

Lansing Street Advisors first reported a position in AZN in Q1 2022 and has held it in 6 quarters since. 1,090 funds tracked by Wall St. Rank hold AZN as of Q2 2023.

Lansing Street Advisors held 240 shares of AstraZeneca worth $34.3K as of Q2 2023.
Lansing Street Advisors left its AstraZeneca share count unchanged in Q2 2023.
AstraZeneca made up 0.02% of Lansing Street Advisors's portfolio in Q2 2023, its #157 holding.
Lansing Street Advisors first reported a position in AstraZeneca in Q1 2022 and has held it in 6 quarters since.
1,090 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2023.

Based on Lansing Street Advisors's 13F filing for Q2 2023, filed 11 Aug 2023.